共 50 条
- [1] Immunohistochemical Tumor Expression Predicts Response to CD3xCD20 Bispecific Antibodies in Patients with Relapsed/Refractory B Cell LymphomaBLOOD, 2023, 142Kyvsgaard, Emil RamsoClausen, Michael RoostRiley, Anna Caroline HasselbalchNiemann, Carsten UtoftSjo, LeneGronbaek, KirstenHutchings, MartinHusby, Simon
- [2] Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II TrialJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (12) : 2238 - +Thieblemont, CatherinePhillips, TycelGhesquieres, HerveCheah, Chan Y.Clausen, Michael RoostCunningham, DavidDo, Young RokFeldman, TatyanaGasiorowski, RobinJurczak, WojciechKim, Tae MinLewis, David Johnvan der Poel, MarjoleinPoon, Michelle LimeiStirner, Mariana CotaKilavuz, NurgulChiu, ChristopherChen, MenghuiSacchi, MarianaElliott, BrianAhmadi, TahamtanHutchings, MartinLugtenburg, Pieternella J.
- [3] Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphomaEXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (08) : 705 - 715Ahmed, GulrayzFurqan, FateehaNasrollahi, ElhamHamadani, Mehdi
- [4] CAR T-Cell Therapy for Relapsed/Refractory Aggressive Large B-Cell LymphomaCLINICAL JOURNAL OF ONCOLOGY NURSING, 2022, 26 (06) : 597 - 601Gideon, Jacklyn
- [5] CD3xCD20 Bispecific Antibodies Yields Long-Term Survival in Relapsed/Refractory B Cell Lymphoma: A Follow-up Study of Patients Treated in Pivotal Phase 1/2 TrialsBLOOD, 2023, 142Kyvsgaard, Emil RamsoClausen, Michael RoostRiley, Anna Caroline HasselbalchNiemann, Carsten UtoftGronbaek, KirstenHutchings, MartinHusby, Simon
- [6] Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20xCD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphomaJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (03)Brouwer-Visser, JurriaanFiaschi, NathalieDeering, Raquel P.Cygan, Kamil J.Scott, DariusJeong, SeBoucher, LaurenGupta, Namita T.Gupta, SurajAdler, ChristinaTopp, Max S.Bannerji, RajatDuell, JohannesAdvani, Ranjana H.Flink, Dina M.Chaudhry, AafiaThurston, GavinAmbati, Srikanth R.Jankovic, Vladimir
- [7] Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphomaBLOOD, 2016, 127 (11) : 1410 - 1416Viardot, AndreasGoebeler, Marie-ElisabethHess, GeorgNeumann, SvenjaPfreundschuh, MichaelAdrian, NicoleZettl, FlorianLibicher, MartinSayehli, CyrusStieglmaier, JuliaZhang, AliciaNagorsen, DirkBargou, Ralf C.
- [8] Safety and Efficacy of a-319 (a CD3xCD19 T cell engager) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin LymphomaBLOOD, 2023, 142Liu, Wei PingJiang, BoShuang, Yue RongZhao, XingZhong, Xuan FanTan, YingYu, Guo JianXue, Sheng JieShen, Wu ZhongTu, Gui YunYang, ZhengChen, Han YangXu, JasonLiu, ShuiYan, Xiao Qiang QiangZhu, JunSong, Yu Qin
- [9] Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell LymphomaJOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (10) : 1131 - +Smits, Nicole C.Sentman, Charles L.
- [10] A CD19/CD20-Directed Bispecific CAR-T Cell Therapy in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)BLOOD, 2023, 142Larson, Sarah M.Chen, Yvonne Y.Johnston, JimRoy, SylvainPatel, PinakinBenjamin, Jonathan E.